Open AccessClinical Efficacy of Infliximab in Patients With Crohn Disease in Different Locations of Disease Pathology: A Meta-Analysis
Author(s) -
Chizhou Jiang,
Wen-Liang Yu,
Hua Zhang
Publication year - 2021
Publication title -
clinical and investigative medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.391
H-Index - 47
eISSN - 1488-2353
pISSN - 0147-958X
DOI - 10.25011/cim.v44i2.36356
Subject(s) - medicine , infliximab , meta analysis , crohn's disease , disease , inflammatory bowel disease , gastroenterology
Purpose: Infliximab (INX) has been approved for treating Crohn disease (CD) for many years, showing promis-ing efficacy in the clinic. However, the efficacy of the drug and the prognosis of CD vary significantly with dif-ferent locations of disease pathology. This study evaluated the efficacy of INX and prognosis in CD in different locations of disease pathology using systematic meta-analysis.
Methods: We used “Infliximab OR Remicade OR Avakine OR Inflectra OR Renflexis OR Remsima OR IgG1k monoclonal antibody” AND “Crohn’s disease OR IBD OR inflammatory bowel disease” as search strategies for searching in PubMed, Wanfang and Embase. A systematic meta-analysis for overall proportions was used to analyze the data.
Results: Twelve studies involving 1,978 patients were included. The results confirmed that treatment with INX led to high clinical remission rates (82%, 95% CI: 64%-92%) and low relapse rates (4%, 95% CI: 2%-9%) in patients with CD. Our results also indicated that use of INX in patients with colon only (L2) CD led to lower clinical remission rates, and use of INX in patients with ileum and colon (L3) CD led to higher relapse rates.
Conclusion: Our findings show different remission rates depending on location of the disease and may be useful for clinicians’ choice of therapeutics.